Fuda Cancer Hospital
Rhabdomyosarcoma treatment cost in China typically runs from $85,000 to $142,000 for comprehensive care. Essential procedures like the removal of rhabdomyosarcoma range from $24,500 to $49,500. Total expenses depend on the tumor stage, required therapy cycles, and clinic tier. Patients often find 40% to 60% savings compared to the US. Top cities for this treatment include Guangzhou, Shanghai, and Beijing.
Typical Rhabdomyosarcoma Treatment Costs in China
Bookimed Expert Insight: Advanced stage patients should prioritize clinics specializing in late-stage oncology. Fuda Cancer Hospital offers specialized cryosurgery and NanoKnife technologies for complex cases. For pediatric or adult radiation needs, Dr. Liu Shi Xin at Xiamen Humanity Hospital provides internationally recognized expertise in IMRT. These JCI-accredited facilities offer a high-value alternative for patients needing multidisciplinary care beyond standard chemotherapy protocols.
| China | Turkey | Austria | |
| Removal of rhabdomyosarcoma | from $24,500 | from $15,000 | from $30,000 |
| Radiation therapy for colorectal cancer | from $11,500 | from $7,000 | from $12,000 |
| Radiation Therapy for Sarcomas | from $10,500 | from $3,250 | from $18,000 |
| Chemotherapy for breast cancer | from $14,800 | from $1,200 | from $15,000 |
| Complex treatment of rhabdomyosarcoma | from $85,000 | from $45,000 | - |
No hidden fees – just official clinic prices. Pay at the clinic for Rhabdomyosarcoma treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Rhabdomyosarcoma treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Rhabdomyosarcoma treatment journey.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
The doctor is a renowned expert in minimally invasive cryosurgery for cancer, serving as President and chief surgeon at Fuda Cancer Hospital since 2001. With a focus on oncology and minimally invasive procedures, the doctor has performed nearly 10,000 cryosurgeries and 500 NanoKnife procedures, treating patients aged 4 to 94.
Graduating from The Fourth Military Medical University with a specialty in thoracic and cardiac surgery, the doctor has contributed significantly to the field with over 100 published papers. Recognized with awards for outstanding contributions to cryosurgery, the doctor holds vice-presidential roles in both the Asian and International Societies of Cryosurgery.
Leading Chinese oncology centers follow international protocols by utilizing the CCCG-RMS framework. This structure directly aligns with the US Children Oncology Group and European standards. Multi-disciplinary teams in cities like Guangzhou and Xiamen use standardized risk stratification. These methods match global diagnostic metrics.
Bookimed Expert Insight: A major quality signal in China is the presence of specialized pediatric supervisors. Professor Liu Shi Xin at Xiamen Humanity Hospital holds doctoral supervisor status and national honors. This level of seniority often correlates with high-volume centers that manage complex, rare pediatric sarcomas. Choosing a facility with JCI accreditation ensures rigorous international safety and administrative standards are met.
Patient Consensus: Families emphasize that verifying pathology and staging results is the most critical first step. They note that survival success depends heavily on a hospital's ability to coordinate surgery and radiation in one location.
Standard chemotherapy cycles in China typically follow a 21-day or 28-day schedule. Practitioners prioritize inpatient administration for the first 1 to 3 days of each cycle. This model allows for intensive hydration and clinical monitoring. It adheres to established Chinese Society of Clinical Oncology (CSCO) protocols.
Bookimed Expert Insight: China's oncology infrastructure is built for high-volume standardized care. Fuda Cancer Hospital alone treats over 30,000 international patients. This scale allows clinics to offer over 10 types of minimally invasive therapies. These often serve as alternatives or adjuncts to traditional chemotherapy. Patients should confirm if their protocol includes these specialized interventions early.
Patient Consensus: Parents of pediatric patients note that cycles often depend on blood count recovery. They emphasize that hospital workflows are very fast and standardized. Expect frequent blood labs and bundled supportive care like growth-factor shots during the rest period.
Proton beam therapy is available for rhabdomyosarcoma in China. Major oncology hubs in Shanghai and Guangzhou utilize this precision radiation. These centers effectively treat pediatric and adult soft-tissue sarcomas. Key technologies include active pencil beam scanning and intensity-modulated proton therapy.
Bookimed Expert Insight: While several Chinese centers possess proton technology, expertise in pediatric cases varies significantly. Dr. Liu Shi Xin at Xiamen Humanity Hospital holds leadership roles in national particle therapy committees. Working with a doctor of this caliber ensures the treatment plan aligns with rigorous national standards. Patients should prioritize centers where the radiation lead has extensive experience in both oncology and particle therapy.
Patient Consensus: Families often seek proton therapy specifically to reduce long-term side effects in children. Patients note that finding a high-volume sarcoma team is as vital as the technology itself.
Top hospitals for rhabdomyosarcoma in China include JCI-accredited Fuda Cancer Hospital and Xiamen Humanity Hospital. These centers specialize in multidisciplinary pediatric oncology. They utilize advanced therapies like cryosurgery and precise radiation. Many facilities integrate international protocols to improve outcomes for rare soft tissue sarcomas.
Bookimed Expert Insight: Patient data shows that choosing a hospital with high international volume like Fuda is vital. This clinic has served patients from over 100 countries. Such centers often have more experience with the logistics needed for rare sarcoma cases. They typically offer more flexible, minimally invasive options than standard public hubs.
Patient Consensus: Families emphasize starting treatment with a sarcoma-aware biopsy to avoid surgical complications. Many recommend prioritizing large referral hospitals that host dedicated multidisciplinary tumor boards for rare cancers.
China is a global hub for pediatric oncology trials and novel targeted therapies. The National Medical Products Administration fast-tracks over 60% of oncology agents. Patients access chimeric antigen receptor cell therapies and tyrosine kinase inhibitors. Specialized centers in Guangzhou and Xiamen offer advanced molecular profiling for rare sarcomas.
Bookimed Expert Insight: While trials are numerous, access at centers like Fuda Cancer Hospital depends on specific hospital-run protocols. Our data shows oncology hospitals in China frequently apply over 10 types of minimally invasive therapies. This volume suggests patients should prioritize academic centers with JCI accreditation to ensure rigorous clinical trial standards.
Patient Consensus: Patients emphasize that molecular profiling is a necessary first step before pursuing targeted therapy. Many note that language barriers and record translations are significant hurdles when accessing experimental protocols.
Chinese sarcoma centers provide advanced localized therapies including High-Intensity Focused Ultrasound, cryosurgery, and NanoKnife. These minimally invasive techniques target tumors while preserving healthy tissue and organ function. JCI-accredited facilities like Fuda Cancer Hospital combine these procedures with precision radiotherapy to manage complex or recurrent rhabdomyosarcoma cases effectively.
Bookimed Expert Insight: Patient data from Fuda Cancer Hospital highlights a significant trend toward multi-modality local control. Clinics often employ over 10 types of minimally invasive therapies. This approach is specifically used for late-stage cancers to avoid intensive chemotherapy. Choosing centers with high patient volumes, like those serving over 30,000 international patients, ensures access to these concentrated technologies under one roof.
Patient Consensus: Patients note that Chinese centers often prioritize limb-sparing reconstructions over amputation for large tumors. Many families appreciate the willingness to perform repeat local treatments for recurrences rather than switching solely to systemic palliative care.